India's Sun Pharma gets US nod for Namenda generic

MUMBAI, April 10 (Reuters) - Indian drugmaker Sun Pharmaceuticals said on Saturday its unit had received tentative U.S. regulatory approval to market a generic version of Forest Laboratories' Namenda tablets.

The tablets are used in the treatment of Alzheimer's disease, the company said in a statement to the stock exchange.

(Reporting by Swati Pandey; Editing by Susan Fenton)

(([e-mail]; [phone], Reuters Messaging: [e-mail])) Keywords: SUN GENERIC/ (If you have a query or comment on this story, send an email to [e-mail]) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.